Evidence map›Paper›PMID 41060481›Full record

ArticleDigestive diseases and sciences2026

State-Level Variability in Location of Death of Patients with End-Stage Liver Disease.

Julia Meguro, Michael Huber, David Goldberg

Abstract read
In one paragraph

Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Julia MeguroDepartment of Medicine, University of Illinois, Chicago, USA.
Michael HuberDivision of Geriatrics and Palliative Medicine, Department of Medicine, University of Miami Miller School of Medicine, Miami, USA.
David GoldbergDivision of Digestive Health and Liver Diseases, Department of Medicine, University of Miami Miller School of Medicine, Don Soffer Clinical Research Center, 1120 NW 14th St., Room 807, Miami, FL, 33136, USA. dsgoldberg@miami.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAlthough deaths from end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC) in the United States increasingly occur at home or in hospice, inpatient medical facility deaths remain high. Despite the decrease in in-hospital deaths for all causes, non-White decedents are more likely than White decedents to die in a hospital setting. This study aimed to determine state-level variability in the location of death among patients with ESLD and HCC and to assess racial/ethnic differences in these patterns, focusing on Black, White, and Hispanic/Latino patients.

methodsA retrospective cross-sectional analysis was conducted using 2018-2022 data from the Centers for Disease Control and Prevention Wide-Ranging OnLine Data for Epidemiologic Research. The proportion of patients with ESLD, HCC, and both conditions who died at an inpatient medical facility, home, hospice facilities, and a combination of both home and hospice was calculated, stratified by race/ethnicity. Mapping was utilized to compare these proportions across the US.

resultsThere was notable geographic variation in the location of death across all groups. Black and Hispanic/Latino patients with ESLD and HCC more frequently died in inpatient facilities compared to White patients. A statistically significant positive correlation was observed between the number of registered hospice agencies in a state and the proportion of deaths occurring at home among White (Spearman's ρ = 0.33, p = 0.02) and Hispanic/Latino patients (Spearman's ρ = 0.38, p = 0.01).

conclusionsFuture research should investigate factors driving interstate variability and racial differences in end-of-life care for ESLD and HCC patients, which may include hospice availability and the presence of palliative care laws. Strategies to reduce these differences and enhance access to quality end-of-life care for all, particularly for racial/ethnic minorities, are needed.

Indexed as

Carcinoma, HepatocellularEnd Stage Liver DiseaseLiver NeoplasmsAgedBlack or African AmericanCross-Sectional StudiesFemaleHispanic or LatinoHospicesHospital MortalityHumansMaleMiddle AgedRetrospective StudiesTerminal CareUnited StatesEnd-of-life careEnd-stage liver diseaseHepatocellular carcinomaHospice

Identifiers

PMID41060481
PMCPMC12982227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.